Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
| Autor: | Heusner TA; Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. till.heusner@uni-due.de, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2009 Oct; Vol. 36 (10), pp. 1543-50. Date of Electronic Publication: 2009 May 05. |
| DOI: | 10.1007/s00259-009-1145-6 |
| Abstrakt: | Purpose: The aims of this study were (1) to evaluate FDG PET/CT and CT for the detection of axillary lymph node metastases in breast cancer (BC) patients and (2) to evaluate FDG PET/CT as a pre-test for the triage to sentinel lymph node biopsy (SLNB) versus axillary lymph node dissection (ALND). Methods: The sensitivity, specificity, positive and negative predictive value (PPV, NPV), and accuracy of FDG PET/CT and CT for axillary lymph node metastases were determined in 61 patients (gold standard: histopathology). According to the equation "NPV = specificity (1-prevalence) / [specificity (1-prevalence) + (1-sensitivity) prevalence]" FDG PET/CT was evaluated as a triage tool for SLNB versus ALND. Results: The sensitivity, specificity, PPV, NPV and accuracy of FDG PET/CT was 58, 92, 82, 77 and 79% and of CT 46, 89, 72, 71 and 72%, respectively. Patients with an up to approximately 60% risk for axillary lymph node metastases appear to be candidates for SLNB provided that the axilla is unremarkable on FDG PET/CT. Conclusion: FDG PET/CT cannot replace invasive approaches for axillary staging but may extend the indication for SLNB. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|